The efficacy of SGLT2 inhibitor switching from thiazolidine about body weight and metabolic-related factors in type 2 diabetes patients

Trial Profile

The efficacy of SGLT2 inhibitor switching from thiazolidine about body weight and metabolic-related factors in type 2 diabetes patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 24 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top